Interferon leukocyte human liquid - instructions for use, dose, side effects, contraindications

Interferon alfa (human leukocyte interferon) is a group of proteins synthesized by leukocytes of donor blood under the influence of the interferon-inducer virus purified by a micro- and ultrafiltration method.

Composition in 1 ml:

active ingredient:

- Interferon alfa (human leukocyte interferon) - 1 thousand ME;

auxiliary components:

- sodium chloride - 0.09 mg;

- sodium dihydrogen phosphate dihydrate - 0.06 mg;

- sodium hydrophosphate dodecahydrate - 0.003 mg;

- water for injection-up to 1 ml.

Description:The solution is from colorless to light pink in color.

Pharmacotherapeutic group:Cytokine

ATX: & nbsp

L.03.A.B.01 Interferon alfa

Pharmacodynamics:

Interferon alfa has the following action:

- antiviral (influenza, herpes, adenovirus infections, etc.);

- antibacterial (bacteriostatic) against mixed infections;

- immunomodulating (normalizes the immune status);

- immunostimulating (enhances the immune response);

- anti-inflammatory.

Interferon alfa from normal human leukocytes has an indirect antiviral effect, consisting in the creation of protective mechanisms in virus-uninfected cells: a change in the properties of cell membranes that prevent the virus from entering the cell; initiation of the synthesis of the series. specific enzymes that prevent the replication of viral RNA and the synthesis of proteins of the virus.

Pharmacokinetics:

The main properties of interferon alfa are used for therapeutic purposes. Interferon alfa inhibits the replication and transcription of viruses and chlamydiae. It has an antiviral effect, inducing in the cells a state of resistance to viral infections and modulating the response of the immune system, aimed at neutralizing the viruses or destroying the cells infected by them. The mechanism of antiviral action is to create protective mechanisms in virus-uninfected cells. By binding to specific receptors on the cell surface, interferon alfa changes the properties of the cell membrane, prevents the adhesion and penetration of the virus into the cell, stimulates specific enzymes, acts on RNA and inhibits the synthesis of proteins of the virus. Suppresses the replication of viruses in an infected cell. These properties of interferon alpha allow him to participate effectively in the processes of eliminating the pathogen, preventing infection and possible complications. Thanks immunomodulating activity Interferon alfa, the normalization of the immune status occurs. Immunomodulating effect is due to stimulation of macrophage activity (phagocytic activity) and natural killer cells (NKcells). Stimulates the process of presentation of the antigen by macrophages to immunocompetent cells.Natural killer cells participate in the immune response of the body to tumor cells. Under the influence of interferon alpha, the activity of T-helpers, cytotoxic T-lymphocytes, expressing antigens of MHC I and II type, as well as the intensity of differentiation of B-lymphocytes, increases in the body. Activation of leukocytes ensures their active participation in the elimination of primary pathological foci and provides recovery of secretory immunoglobulin A.

Indications:

Prevention and treatment of influenza and other acute respiratory viral infections.

Contraindications:

The drug has no contraindications when administered through the respiratory tract.

Carefully:

Use with caution persons with hypersensitivity to antibiotics and with increased sensitivity to preparations of protein origin, including chicken meat, to chicken eggs.

With caution: people with allergic diseases in the anamnesis.

Pregnancy and lactation:

During pregnancy and during lactation, Interferon is prescribed only if the expected effect for the mother exceeds the risk to the fetus.

Dosing and Administration:

To prevent influenza and other acute respiratory viral infections, use the drug by spraying or instilling an aqueous solution. Introduction in the form of injections is strictly prohibited.

The ampoule or vial with the drug should be opened immediately, before use. The opened ampoule with the drug can be stored at a temperature of 2 to 8 ° C for no more than one day. The opened vial, neatly closed with a dropper of polymeric material, can be stored at a temperature of 2 to 8 ° C for up to three days.

Spraying of the drug can be carried out by sprayers of any system. For children and adults, the same dosing regimen is used. When instilling the drug, inject 5 drops into each nasal passage 2 times a day with an interval of at least 6 hours.

When treating the drug, use it by inhalation, spraying or instillation. For children and adults, the same dosing regimen is used. The most effective way is inhalation. For, it is recommended to use inhalers, equipped with electric heating, or another system. For one injection, use the contents of 3 ampoules of the drug, to which add 4 ml of water. The solution should be heated to a temperature not exceeding 37 ° C.Inhalation, the drug is administered 2 times a day with an interval of at least 6 hours. When instilling the drug, inject 0.25 ml (5 drops) into each nasal passage 1-2 hours, at least 5 times a day, for 2-3 days.

Precautions for use:

Parenteral administration of the drug is strictly prohibited. Inhalation is recommended by inhalators equipped with heating.

Side effects:Allergic reactions (urticaria, polymorphic rash, etc.).

Overdose:Cases of an overdose have not been revealed.

Interaction:In experiments in tissue culture conducted in the laboratory of antibiotics, it was found that the combined use of methyluracil with interferon leukocyte human liquid observed a pronounced synergistic effect. A pronounced synergistic effect is observed when a human leukocyte interferon is combined with lysozyme.

Special instructions:For the prevention of the introduction of the drug should be started with an immediate threat of infection and continue as long as the risk of infection persists. For the purpose of treatment, the drug should be used at an early stage of the disease when the first clinical symptoms appear.

Effect on the ability to drive transp. cf. and fur:Not found.

Form release / dosage:Solution for intranasal administration and inhalations, 1000 IU / ml.

Packaging:In ampoules of 2, 5 ml (1000 IU / ml) or glass bottles complete with a dropper of polymeric material or bottles of polymeric material with a dropper. The package contains 5, 10, ampoules or 1, 5, 10 vials, instructions for use, ampoule scapegrator (when released in ampoules). When using ampoules with a ring or break point, the ampoule scaper is not inserted.

Storage conditions:The preparation is stored and transported in accordance with SP 3.3.2.1248-03 at a temperature of 2 to 10 ° C.

Shelf life:The preparation is stored and transported in accordance with SP 3.3.2.1248-03 at a temperature of 2 to 10 ° C.

Terms of leave from pharmacies:On prescription

Registration number:P N002335 / 01

Date of registration:26.05.2008 / 31.03.2016

Expiration Date:Unlimited

The owner of the registration certificate:BIOMED them. I.I.Mechnikova, OJSC BIOMED them. I.I.Mechnikova, OJSC Russia

Manufacturer: & nbsp

BIOMED them. I.I.Mechnikova, OJSC Russia

Information update date: & nbsp27.10.2017

Illustrated instructions

Instructions

Interferon leukocyte human fluid (Interferon leukocytic human fluid)